Launched by two brothers who had successfully (and separately) grown to acqusition status other small firms, Eradivir - aPurdue spinout - specializes in the discovery and development of dual-action antiviral drugs. These drugs simultaneously inhibit reproduction of the targeted virus and redirect the immune system to destroy the virus and the virus-infected host cells. This small molecule or âminiBITâ technology provides a flexible platform that can effectively treat the majority of pathologic viruses, including influenza, multiple coronaviruses, hepatitis B, HIV and RSV. At the time of founding, Eradavir eas described as a therapeutics company intended to offer a non-immunological targeting agent for use against the virus that causes COVID-19. The company offer ligands with high specificity and avidity for a unique domain of the spike protein found on most coronaviruses including COVID-19, enabling the medical industry to eliminate all free virus and virus-infected cells, even in late-stage infecti
